Wolfgang Froestl

EPFL Innovation Park, Building B
Lausanne, VD 1015, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Discovery and characterization of novel indole and 7-azaindole derivatives as inhibitors of β-amyloid-42 aggregation for the treatment of Alzheimer's disease.

Discovery and characterization of novel indole and 7-azaindole derivatives as inhibitors of β-amyloid-42 aggregation for the treatment of Alzheimer's disease.

Journal: Bioorganic & medicinal chemistry letters

Published: December 14, 2016

Synthesis and structure-activity relationship of 2,6-disubstituted pyridine derivatives as inhibitors of β-amyloid-42 aggregation.

Synthesis and structure-activity relationship of 2,6-disubstituted pyridine derivatives as inhibitors of β-amyloid-42 aggregation.

Journal: Bioorganic & medicinal chemistry letters

Published: March 21, 2016

Cognitive enhancers (Nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. Disease-modifying drugs. Update 2014.

Cognitive enhancers (Nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. Disease-modifying drugs. Update 2014.

Journal: Journal of Alzheimer's disease : JAD

Published: July 26, 2014

Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes. Update 2014.

Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes. Update 2014.

Journal: Journal of Alzheimer's disease : JAD

Published: June 07, 2014

Cognitive enhancers (Nootropics). Part 1: drugs interacting with receptors. Update 2014.

Cognitive enhancers (Nootropics). Part 1: drugs interacting with receptors. Update 2014.

Journal: Journal of Alzheimer's disease : JAD

Published: June 06, 2014

Increased efflux of amyloid-β peptides through the blood-brain barrier by muscarinic acetylcholine receptor inhibition reduces pathological phenotypes in mouse models of brain amyloidosis.

Increased efflux of amyloid-β peptides through the blood-brain barrier by muscarinic acetylcholine receptor inhibition reduces pathological phenotypes in mouse models of brain amyloidosis.

Journal: Journal of Alzheimer's disease : JAD

Published: September 28, 2013

Cognitive enhancers (nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. disease-modifying drugs.

Cognitive enhancers (nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. disease-modifying drugs.

Journal: Journal of Alzheimer's disease : JAD

Published: November 29, 2012

Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes.

Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes.

Journal: Journal of Alzheimer's disease : JAD

Published: October 09, 2012

Discovery and structure activity relationship of small molecule inhibitors of toxic β-amyloid-42 fibril formation.

Discovery and structure activity relationship of small molecule inhibitors of toxic β-amyloid-42 fibril formation.

Journal: The Journal of biological chemistry

Published: August 15, 2012

Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors.

Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors.

Journal: Journal of Alzheimer's disease : JAD

Published: August 14, 2012

6-Amino quinazolinedione sulfonamides as orally active competitive AMPA receptor antagonists.

6-Amino quinazolinedione sulfonamides as orally active competitive AMPA receptor antagonists.

Journal: Bioorganic & medicinal chemistry letters

Published: October 21, 2011

An historical perspective on GABAergic drugs.

An historical perspective on GABAergic drugs.

Journal: Future medicinal chemistry

Published: March 25, 2011

Showing 1-12 of 13

Last Updated: 09/26/2026